Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about apolipoprotein_E: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| amyloid_clearance | regulates | pathway | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| APOE | encodes | gene | 0.80 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | 0.718 | neurodegeneration | Blood-brain barrier transport mechanisms |
| Apolipoprotein E4-Mediated Metabolic Dysfunction Correction | 0.380 | metabolomics | Metabolomic signatures of neurodegenerat |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| AD Combination Therapy Trial: Anti-Aβ + Anti-Tau | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $180,000 |
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| ApoE4 Function in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $360,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Metal Ion Homeostasis Dysregulation in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Sex Differences in Alzheimer's Disease — mechanisms and therapeutic im | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 1 |
| ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] | Raulin AC, Doss SV, Trottier ZA, Ikezu T | Mol Neurodegener | 2022 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventin [PMID:30595089] | Brophy ML, Dong Y, Tao H, Yancey PG, Son | Circ Res | 2019 | 1 |
| Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical [PMID:28381441] | Shinohara M, Tachibana M, Kanekiyo T, Bu | J Lipid Res | 2017 | 1 |
| APOE-Targeted Therapeutics for Alzheimer's Disease. [PMID:41224653] | ["Yassine H", "Hugo C", "O'Donovan B", " | The Journal of neuroscience : | 2025 | 0 |
| Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker [PMID:39841474] | ["Oomens J", "van Gils V", "Vos S", "Fre | JAMA network open | 2025 | 0 |
| AMBP protects against aortic valve calcification by inhibiting ERK1/2 and JNK pa [PMID:40225558] | ["Guo C", "Liu X", "Mei Z", "Chang M", " | Theranostics | 2025 | 0 |
| Blood-based pre-screening in the SKYLINE secondary prevention Ph3 gantenerumab s [PMID:41085131] | ["Bauer A", "Rabe C", "Schiffman C", "Ro | Alzheimer's & dementia : the j | 2025 | 0 |
| ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetr [PMID:40987376] | Ge T, Niu A, Lv Y, Chen Y, Liu Y, Lei X, | Journal of controlled release | 2025 | 0 |
| Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alv [PMID:38671323] | ["Theobald H", "Bejarano D", "Katzmarski | Nature immunology | 2024 | 0 |
| C/EBPβ: A transcription factor associated with the irreversible progression of A [PMID:38644578] | ["Yao Q", "Long C", "Yi P", "Zhang G", " | CNS neuroscience & therapeutic | 2024 | 0 |
| Cholesterol Metabolism in Pancreatic Cancer. [PMID:37958351] | ["Rebelo A", "Kleeff J", "Sunami Y"] | Cancers | 2023 | 0 |
| Apoe4 and Alzheimer's Disease Pathogenesis-Mitochondrial Deregulation and Target [PMID:36614219] | ["Pires M", "Rego A"] | International journal of molec | 2023 | 0 |
| Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. [PMID:35750033] | ["Tcw J", "Qian L", "Pipalia N", "Chao M | Cell | 2022 | 0 |
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 0 |
| Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanis [PMID:32849290] | Basu D, Bornfeldt KE | Frontiers in endocrinology | 2020 | 0 |
| Contribution of astrocytes to metabolic dysfunction in the Alzheimer's disease b [PMID:31188740] | ["Zulfiqar S", "Garg P", "Nieweg K"] | Biological chemistry | 2019 | 0 |
| Megalin mediates plasma membrane to mitochondria cross-talk and regulates mitoch [PMID:29916093] | ["Li Q", "Lei F", "Tang Y", "Pan J", "To | Cellular and molecular life sc | 2018 | 0 |
| A phase 3 trial of IV immunoglobulin for Alzheimer disease. [PMID:28381506] | ["Relkin N", "Thomas R", "Rissman R", "B | Neurology | 2017 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning apolipoprotein_E in their description or question text
No additional research found